AEON Biopharma, Inc. (AEON) Key Statistics & Financial Ratios

AEON Biopharma, Inc. (AEON) — Price $0.26 HealthcareBiotechnology — AMEX

Latest reported results:

Key statistics dashboard for AEON Biopharma, Inc. (AEON). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc.

Stock Data

Price$0.26
Market Cap$11M
Enterprise Value$10.7M
Beta0.73
ExchangeAMEX
CountryUS

Valuation Multiples

P/E Ratio-0.07
Price / Book-0.85
P/S0.00
EV/EBITDA-0.42
EV/Sales0.00
EV/FCF-0.78
P/FCF-0.83
Earnings Yield-420.62%
FCF Yield-120.21%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity204.18%
Return on Assets-924.25%
Return on Invested Capital1699.74%
Return on Capital Employed1387.57%

Financial Health

Current Ratio0.54
Quick Ratio0.54
Cash Ratio0.47
Debt / Equity-0.18
Debt / Assets46.95%
Net Debt / EBITDA0.03
Interest Coverage0.00
Piotroski F-Score2
Altman Z-Score-126.80

Per-Share Data

Revenue per share0.00
Book Value per share-0.30
Cash per share0.07
FCF per share-0.27
Tangible Book Value per share-0.30
Dividend per share0.00

Analyst Consensus

Strong Buy0
Buy2
Hold0
Sell0
Strong Sell0
Total analysts2
Avg rating (1-5)1.00

Related companies: ABP · APM · BOLT · CING · CLNN · CLRB · LYRA

Explore sector: Healthcare · Biotechnology

More sections of AEON: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks